Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

@article{Hong2010PhaseIS,
  title={Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis},
  author={Junshik Hong and S. -M. Han and Hye Seon Ham and Tae-Yong Kim and In Sil Choi and B Y Kim and Do-youn Oh and Seock-Ah Im and Gyeong Hoon Kang and Yung-jue Bang and T. -Y. Kim},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2010},
  volume={67},
  pages={1323-1331}
}
To evaluate the efficacy and safety of S-1 in combination with oxaliplatin in a biweekly schedule as first-line treatment in metastatic colorectal cancer and the association between genetic polymorphisms and treatment outcomes. Eligibility included age 18–75 years, at least one measurable lesion, no prior chemotherapy except adjuvant chemotherapy, and Eastern Cooperative Oncology Group Performance Status (PS) 0–2. S-1 40 mg/m2 b.i.d. on days 1–7 with 85 mg/m2 of oxaliplatin on day 1 was… CONTINUE READING
8 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…